Acute Lymphoblastic Leukemia Drug Pipeline: 111 Assets by Phase

How many acute lymphoblastic leukemia drugs are in each phase of development?

Douglas Insights counts 6 acute lymphoblastic leukemia candidates in Phase III, 5.4% of the 111 assets in development; Phase II holds 21 and Phase I holds 84.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each acute lymphoblastic leukemia asset appears in exactly one row. The 567 trials still recruiting or running carry 51% of the 1,106 registered trials in scope.

How many acute lymphoblastic leukemia trials are recruiting patients now?

334 acute lymphoblastic leukemia trials are recruiting patients and 75 more have not started recruiting yet, out of 1,106 interventional trials in scope; together they make up 37% of the trial base.

Terminated, suspended and withdrawn acute lymphoblastic leukemia trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the acute lymphoblastic leukemia pipeline?

Beijing Biotech leads the acute lymphoblastic leukemia pipeline with 8 candidates; the top 5 sponsors hold 23% of the 111 assets, and 73 sponsors run at least one.

Industry sponsors lead 217 of the 1,106 acute lymphoblastic leukemia trials (20%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the acute lymphoblastic leukemia pipeline?

Mechanism and drug-type classification for the 111 acute lymphoblastic leukemia candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What acute lymphoblastic leukemia trial readouts are coming next?

12 acute lymphoblastic leukemia candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many acute lymphoblastic leukemia readouts fall in each quarter?

15 acute lymphoblastic leukemia candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 7, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most acute lymphoblastic leukemia trials?

United States hosts the most acute lymphoblastic leukemia trials, with sites in 562 of the 1,106 studies (51%); trials in scope run in 63 countries in all.

A multinational acute lymphoblastic leukemia trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are acute lymphoblastic leukemia drugs being tested?

562 of the 1,106 acute lymphoblastic leukemia trials (51%) have a site in the United States, 194 (18%) in Europe and 268 (24%) in China; 64 of the 111 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational acute lymphoblastic leukemia trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the acute lymphoblastic leukemia pipeline since the last update?

This is the first edition of the acute lymphoblastic leukemia pipeline count, dated 3 Oct 2026. The next refresh is due by 1 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the acute lymphoblastic leukemia pipeline?

Douglas Insights read 1,106 interventional trials registered on ClinicalTrials.gov for the conditions "precursor cell lymphoblastic leukemia-lymphoma", "acute lymphoblastic leukemia" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 111 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the acute lymphoblastic leukemia pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage